Patent intelligence · US
US 20260097057
COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE AND LIVER FIBROSIS
COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE AND LIVER FIBROSIS
Patent details — US 20260097057
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 9, 2026
- Expiration
- Apr 4, 2046
- Applicant
- ASTRAZENECA AB [SE]
- CPC classes
- A61K 31/ 497 A I, A61K 31/ 7034 A I, A61K/31497, A61K/3170
Quick answer
US 20260097057 (COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE AND LIVER FIBROSIS) is held by ASTRAZENECA AB [SE]. Status: granted. Granted Apr 9, 2026. Expires Apr 4, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ASTRAZENECA AB [SE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 497 A I, A61K 31/ 7034 A I, A61K/31497, A61K/3170, A61K/317034, A61P 1/ 16 A I
More from ASTRAZENECA AB [SE]
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 20260097057?
US 20260097057 (COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE AND LIVER FIBROSIS) is held by ASTRAZENECA AB [SE]. Status: granted. Granted Apr 9, 2026. Expires Apr 4, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 20260097057?
ASTRAZENECA AB [SE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 20260097057 expire?
Our index shows an expiration date of Apr 4, 2046 (20 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.